← Back to All Stocks

MRK - Merck & Co., Inc.

Health Care

Price History

About

Industry

Drug Manufacturers - General

Employees

73,000

Headquarters

United States


Company Overview

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Price

$120.29

52-Week Range

$73 $125

Dividend Yield

2.88%

Dividend Score

A

Dividend

Yield 2.88%
Annual $3.40
Payout 45%
5Y Avg 3.03%

Valuation

P/E (TTM) 16.2
Fwd P/E 12.3
P/B 5.66
PEG 0.80

Profitability

Profit Margin 28.1%
Op Margin 32.8%
ROE 36.9%
ROA 12.0%

Financial Health

Current Ratio 1.54
Quick Ratio 0.96
Debt/Equity 96%

Cash Flow

Free CF $11.9B
Op CF $16.5B
Total Cash $14.6B

Analyst Consensus

Buy

27 analysts

Target: $128 $100 - $150
+6.4% implied

Dividend Growth

Most Recent Annual Growth

5.13%

3-Year Avg Growth

5.42%

5-Year Avg Growth

6.76%

Annual Dividends

Year-over-Year Growth

Recent Dividend History

Ex-Dividend Date Amount
Mar 16, 2026 $0.8500
Dec 15, 2025 $0.8500
Sep 15, 2025 $0.8100
Jun 16, 2025 $0.8100
Mar 17, 2025 $0.8100
Dec 16, 2024 $0.8100
Sep 16, 2024 $0.7700
Jun 17, 2024 $0.7700
Mar 14, 2024 $0.7700
Dec 14, 2023 $0.7700
Sep 14, 2023 $0.7300
Jun 14, 2023 $0.7300
Mar 14, 2023 $0.7300
Dec 14, 2022 $0.7300
Sep 14, 2022 $0.6900
Jun 14, 2022 $0.6900
Mar 14, 2022 $0.6900
Dec 14, 2021 $0.6900
Sep 14, 2021 $0.6500
Jun 14, 2021 $0.6500

Unlock Full Access

Get unlimited access to all features including our powerful dividend screener, detailed stock analysis, and our dividend growth forecasting tool.

Full Screener

300+ proven dividend growth stocks

Growth Forecasts

Project returns with reinvestment

Deep Analysis

Fundamentals & metrics that matter